MRUS Stock Overview
A clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Merus N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$44.36 |
| 52 Week High | US$61.61 |
| 52 Week Low | US$22.26 |
| Beta | 1.12 |
| 11 Month Change | -16.61% |
| 3 Month Change | -17.23% |
| 1 Year Change | 87.63% |
| 33 Year Change | 67.19% |
| 5 Year Change | 182.70% |
| Change since IPO | 341.78% |
Recent News & Updates
Merus: Petosemtamab Set Up For December 2024 Data Presentation
Nov 05We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely
Sep 20
Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks
Aug 14Recent updates
Merus: Petosemtamab Set Up For December 2024 Data Presentation
Nov 05We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely
Sep 20Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks
Aug 14Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts
Jun 01Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)
May 24Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
May 12Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans
May 10Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement
Mar 01Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up
Feb 01Merus Stock: Rally Seems Overdone
Jan 23Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?
Jan 14Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)
Dec 18We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully
Sep 19Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price
Jun 20Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?
May 24Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate
Feb 08Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M
Aug 08Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies
Aug 02Merus: Precision Oncology Pioneer Continues To Execute In The Clinic
Jun 30Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)
May 14Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business
Apr 25New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)
Mar 03We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn
Nov 25News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts
Aug 08Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)
Jul 28We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate
Jul 02Shareholder Returns
| MRUS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -10.7% | -6.5% | -1.0% |
| 1Y | 87.6% | 14.6% | 30.3% |
Return vs Industry: MRUS exceeded the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: MRUS exceeded the US Market which returned 30.3% over the past year.
Price Volatility
| MRUS volatility | |
|---|---|
| MRUS Average Weekly Movement | 4.7% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MRUS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MRUS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 201 | Bill Lundberg | www.merus.nl |
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma.
Merus N.V. Fundamentals Summary
| MRUS fundamental statistics | |
|---|---|
| Market cap | US$2.94b |
| Earnings (TTM) | -US$244.56m |
| Revenue (TTM) | US$35.93m |
84.5x
P/S Ratio-12.4x
P/E RatioIs MRUS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRUS income statement (TTM) | |
|---|---|
| Revenue | US$35.93m |
| Cost of Revenue | US$146.08m |
| Gross Profit | -US$110.15m |
| Other Expenses | US$134.41m |
| Earnings | -US$244.56m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.57 |
| Gross Margin | -306.55% |
| Net Profit Margin | -680.61% |
| Debt/Equity Ratio | 0% |
How did MRUS perform over the long term?
See historical performance and comparison